1. 32.4 A NOVEL TREATMENT FOR COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA BY ENHANCING THE ACTIVITY OF PARVALBUMIN INTERNEURONS. (9th April 2019) Authors: Hutchison, John; Howes, Oliver; Marques, Tiago Reis; Kaar, Stephen; van den Berg, Frans; Large, Charles Journal: Schizophrenia bulletin Issue: Volume 45(2019)Supplement 2 Page Start: S142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. T108. AUT00206, A NOVEL KV3 CHANNEL MODULATOR, REDUCES KETAMINE-INDUCED BOLD SIGNALLING IN HEALTHY MALE VOLUNTEERS: A RANDOMISED PLACEBO-CONTROLLED CROSSOVER TRIAL. (9th April 2019) Authors: Deakin, Bill; Perini, Francesca; Nazimek, Jadwiga; McKie, Shane; Hutchison, John; Alvaro, Guiseppe; McFarquhar, Martyn; Turgut, Tolga; Sajjala, Anil; Lovick, Susan; Dourish, Colin; Large, Charles Journal: Schizophrenia bulletin Issue: Volume 45(2019)Supplement 2 Page Start: S245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The effect of AUT00206, a Kv3 potassium channel modulator, on dopamine synthesis capacity and the reliability of [18F]-FDOPA imaging in schizophrenia. (September 2022) Authors: Angelescu, Ilinca; Kaar, Stephen J; Marques, Tiago Reis; Borgan, Faith; Veronesse, Mattia; Sharman, Alice; Sajjala, Anil; Deakin, Bill; Hutchison, John; Large, Charles; Howes, Oliver D Journal: Journal of psychopharmacology Issue: Volume 36:Number 9(2022) Page Start: 1061 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗